08 Sep 2023
Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.
29 Aug 2023
Xbrane Biopharma releases interim report for January – June 2023
29 Aug 2023
XBRANE UPDATES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW ON AN MONTHLY BASIS BEFORE END OF FIRST QUARTER 2025
25 Aug 2023
Invitation to presentation of Xbrane Biopharma’s interim report January – June 2023 on August 29, 2023
25 Jul 2023
Xbrane invites to a webcast today Tuesday, July 25th, 2023
25 Jul 2023
STADA and Xbrane weigh options for ranibizumab biosimilar candidate
21 Jun 2023
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate
15 Jun 2023
Xbrane strengthens its commitment to sustainable business by joining the United Nations Global Compact
31 May 2023
Xbrane Biopharma releases interim report for January – March 2023